Odyssey TherapeuticsODTX +2.01%9 EV-to-FCF is -18.82 as of Jun. 30, 2026. GuruFocus rates ODTX with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 331 Biotechnology companies, Odyssey Therapeutics ranks worse than 302114.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Odyssey Therapeutics's Enterprise Value is $774.98 Mil.
Odyssey Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-41.18 Mil. Therefore, Odyssey Therapeutics's EV-to-FCF for today is -18.82.
The historical rank and industry rank for Odyssey Therapeutics's EV-to-FCF or its related term are showing as below:
ODTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -19.03 Med: -8.3 Max: -7.54
Current: -18.82
During the past 4 years, the highest EV-to-FCF of Odyssey Therapeutics was -7.54. The lowest was -19.03. And the median was -8.30.
ODTX's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs ODTX: -18.82
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Odyssey Therapeutics's PE Ratio (TTM) for today is calculated as:
Odyssey Therapeutics's share price for today is $19.25.
Odyssey Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.811.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Odyssey Therapeutics EV-to-FCF Related Terms
Odyssey Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Odyssey Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Odyssey Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Odyssey Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Odyssey Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Odyssey Therapeutics's EV-to-FCF falls into.
Odyssey Therapeutics's current Enterprise Value is $774.98 Mil.
Odyssey Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Odyssey Therapeutics (ODTX) has a EV-to-FCF of -18.82 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Odyssey Therapeutics and its competitors. According to the industry distribution chart, Odyssey Therapeutics ranks #999999 out of 331 companies in the Biotechnology industry.
Is Odyssey Therapeutics' EV-to-FCF too high?
Odyssey Therapeutics' current EV-to-FCF is -18.82. Based on the distribution chart, Odyssey Therapeutics ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Odyssey Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' EV-to-FCF compare to VOR and PHAT?
According to the Biotechnology industry distribution chart, Odyssey Therapeutics ranks #999999 out of 331 companies for EV-to-FCF. This places Odyssey Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Odyssey Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Odyssey Therapeutics's current EV-to-FCF is -18.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current EV-to-FCF of -18.82. The current EV-to-FCF is -18.82. Odyssey Therapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current EV-to-FCF is -18.82 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
9GF Score
Get the complete analysis for ODTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ODTX has been successfully added to your 